A long-term retrospective cohort-based risk-benefit analysis of augmenting total cumulative I-131 activity to 37GBq in differentiated thyroid cancer patients with skeletal metastases
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0294343 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Sivasankar Kanankulam Velliangiri und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Adenocarcinoma, Follicular. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objective
Skeletal metastases in differentiated thyroid cancer (DTC) patients are associated with poor prognosis. The objective was to determine the maximum I-131 cumulative activity that could be safely administered without compromising efficacy. The secondary objective was to identify other prognostic factors affecting survival outcomes. Materials and methods This was a retrospective cohort study done at a tertiary-care institution comprising of data from January 1990-June 2020. 489 DTC patients having skeletal metastases with ≥12 months follow-up were included. Ninety-six percent of patients had thyroidectomy followed by radioiodine therapy for skeletal metastases. All patients were on oral suppressive levothyroxine tablets. External beam radiotherapy (EBRT) and oral tyrosine kinase inhibitors were used whenever indicated. The main outcome measures were overall survival (OS), progression-free survival (PFS), and adverse-events.
Results
There were 347 (71%) females and 324 (66%) had follicular carcinoma thyroid. Median follow-up was 78 (interquartile range, IQR: 37–153) months. 333 patients (68%) received ≤37GBq I-131 cumulative activity (group 1) and 156 patients (32%) received >37GBq cumulative RAI activity (group 2). Overall median OS and PFS were 74 (95% confidence interval (CI): 62.2–85.8) and 48 (95%CI: 40.5–55.4) months, respectively. The 5-, 10-, 15- and 20-year estimated overall survival probabilities were 55.7%, 28.4%, 14% and 8.3%, respectively. On multivariate analysis, age(
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.
ORCID-Profile: Chandrasekhar Bal
Zitieren
APA
Kanankulam Velliangiri, S., Ballal, S., Prasad Yadhav, M., Tripathi, M., Satapathy, S., & Bal, C. (2023). A long-term retrospective cohort-based risk-benefit analysis of augmenting total cumulative I-131 activity to 37GBq in differentiated thyroid cancer patients with skeletal metastases. PLOS ONE. https://doi.org/10.1371/journal.pone.0294343
Vancouver
Kanankulam Velliangiri S, Ballal S, Prasad Yadhav M, Tripathi M, Satapathy S, Bal C. A long-term retrospective cohort-based risk-benefit analysis of augmenting total cumulative I-131 activity to 37GBq in differentiated thyroid cancer patients with skeletal metastases. PLOS ONE. 2023. doi:10.1371/journal.pone.0294343
BibTeX
@article{KanankulamVelliangiri2023,
author = {Kanankulam Velliangiri, Sivasankar and Ballal, Sanjana and Prasad Yadhav, Madhav and Tripathi, Madhavi and Satapathy, Swayamjeet and Bal, Chandrasekhar},
title = {A long-term retrospective cohort-based risk-benefit analysis of augmenting total cumulative I-131 activity to 37GBq in differentiated thyroid cancer patients with skeletal metastases},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0294343}
}
EUVIMED